Reduction in U.S. direct spending on originator biologics as of 2018

This statistic depicts the projected savings in spending on originator biologics in the U.S. as of 2018. The projections are provided by different agencies for several time ranges. According to the projection by ESI (Express Scripts, Inc.), some 250 billion U.S. dollars will be saved due to the use of biosimilars in the United States between 2014 and 2024.

Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

$39 $59 per month *
in the first 12 months
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

February 2018

Region

United States

Survey time period

as of 2018

Supplementary notes

CBO = Congressional Budget Office;
RAND = RAND Corporation;
QI = QuintilesIMS (IQVIA);
ESI = Express Scripts Inc.
* Actually, the RAND gives a range of 40-93 billion U.S. dollars.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Generics and biosimilars"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.